Varinos buys skin-microbiome startup MySkin to expand beyond fertility
What's the deal? Japanese genomics company Varinos has acquired all shares of MySkin, a startup specialising in genetic analysis of skin bacteria, effective November 1. The deal value was undisclosed. MySkin joins the Varinos group as a wholly owned partner.
What does each do? Varinos is best known for its uterine-flora test, which it says was the world's first and is now used at more than 400 medical institutions in Japan, with over 50,000 samples analysed. MySkin, a University of Tokyo spinout founded in January 2014, holds patented sampling technology and runs contract analysis for cosmetics, pharmaceutical, and research clients.
What's the strategic rationale? The two pair Varinos's clinical implementation and medical network with MySkin's patented skin-sampling technology and industry client base. Combined, they aim to offer genomic test development, analysis, clinical rollout, and corporate research under one roof.
Why now? The move follows Varinos's roughly US$9.62M Series D in May, which it said would fund new business development beyond its core uterine-flora testing. That round included Mitsui ChemicalsDealroom has a profile for this one. Try Dealroom →, with which Varinos announced a research agreement.
What's the endgame? Varinos wants to grow beyond reproductive medicine into skin and wider healthcare markets, selling contract analysis and joint research to cosmetics, drug, and healthcare firms. Services would span basic product research, microbial-flora characterisation, and analysis of bacterial changes before and after product use.
What could go wrong? The purchase price and expected financial contribution were not disclosed, so the deal's significance is chiefly strategic. The announcement alone does not establish commercial scale or clinical impact in the new markets.
"This participation by MySkin in the group is an important step that will further accelerate our growth strategy," said Varinos president Hidetoshi Hirakawa (translated from Japanese).
The signal: Microbiome analysis is spilling out of its clinical origins into consumer-facing industries. By bolting a skin-focused specialist onto a fertility-testing base, Varinos is betting that one genomic platform can serve both patients and the companies building the next wave of cosmetics and healthcare products.
Read more: prtimes.jp
Image credit: USDAgov